{
  "docId": "019de076-8183-75b8-8b2d-7503ba8c42ba",
  "docSlug": "f8cc3498a347f12db8c194c5955f1d44",
  "documentTitle": "Kymera | Investor Presentation Deck | 46 slides",
  "authorId": "kymera",
  "authorName": "Kymera Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 46,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 18,
  "notes": "The slide includes a disclaimer regarding the non-head-to-head nature of the comparison.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-8183-75b8-8b2d-7503ba8c42ba/17",
  "deckHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba",
  "deckJsonHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba.json",
  "deckAnchorHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "*Range from 7 different Phase 2 and Phase 3 trials; **Range from 10 different Phase 2 and Phase 3 trials; 1Simpson EL, et al. NEJM 2016;375:2335-2348; 2Bieber T, et al. NEJM 2021;384:1101-1112; The Dupilumab clinical trial was conducted by other parties in a similar patient population with different enrollment criteria from Part 1C of our Phase 1 clinical trial evaluating KT-474. Results do not reflect a head-to-head trial and are shown for illustrative purposes only",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "89db3efb-9d20-445c-af90-1874d6c5ea63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "Encouraging initial EASI score reductions sustained after cessation of dosing; Peak pruritus reductions, and responder rates, significantly greater than placebo and SOC benchmarks; Investigator Global Assessment (IGA) scores improved in 2 of 7 patients and remained stable in the others",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5af2e21a-0cbf-4761-a691-0372116a2dd9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.9,
        "x": 0.05,
        "y": 0.4
      },
      "kind": "table",
      "text": "Comparison table of KT-474 (Day 28/42) vs Placebo (Week 4) vs Dupilumab (Week 4) for EASI, Peak Pruritus NRS, and Responder rates.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b805ee29-afcf-49d1-a69a-40387e671c7f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.1,
        "y": 0.05
      },
      "kind": "title",
      "text": "KT-474 Showed Meaningful Signs of Clinical Activity in AD, Comparing Favorably to Placebo Benchmarks and SOC",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1e7bb57-e138-4fc0-8d7c-53aee9df61e6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "30b5a48c-f95c-4295-aafe-dbe2b5b7d739",
      "evidence": "Direct comparison of clinical trial data against benchmarks",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 7,
      "beatId": "3821b163-197d-4c86-9367-33b4bd3fb93a",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Desire",
      "beatSlug": "aida-desire",
      "evidence": "The deck showcases the potential for broad activity across multiple diseases, creating desire for Kymera's TPD approach.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 5,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "7b376215-a5b5-4891-ad20-1901edfeffd7",
      "evidence": "The deck presents a clear logical chain from the problem to the solution and potential benefits.",
      "position": 0,
      "objective": "To demonstrate the logic and potential of Kymera's TPD approach",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    },
    {
      "to": 20,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "4c55e1a3-cbe4-4bd4-91f4-d237841a6ee0",
      "evidence": "The deck implies the limitations of current treatments and the potential consequences of not adopting new approaches.",
      "position": 1,
      "objective": "To highlight the cost of inaction and the need for new treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}